CRIS Current Research Information System

FINELLI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.574
AS - Asia 2.800
EU - Europa 2.499
AF - Africa 319
Continente sconosciuto - Info sul continente non disponibili 187
SA - Sud America 132
OC - Oceania 4
Totale 9.515
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.510
SG - Singapore 861
VN - Vietnam 708
CN - Cina 658
GB - Regno Unito 647
IT - Italia 447
SE - Svezia 355
DE - Germania 315
HK - Hong Kong 176
FR - Francia 146
RU - Federazione Russa 132
IN - India 128
JP - Giappone 96
BR - Brasile 92
TG - Togo 92
IE - Irlanda 83
SC - Seychelles 75
NL - Olanda 63
ZA - Sudafrica 61
EE - Estonia 52
BD - Bangladesh 44
FI - Finlandia 44
NG - Nigeria 42
UA - Ucraina 38
CA - Canada 37
CI - Costa d'Avorio 36
HR - Croazia 35
BG - Bulgaria 27
BE - Belgio 26
JO - Giordania 23
AT - Austria 22
CH - Svizzera 20
AR - Argentina 18
EU - Europa 15
PL - Polonia 13
MX - Messico 12
TR - Turchia 11
PK - Pakistan 10
TH - Thailandia 10
ID - Indonesia 9
UZ - Uzbekistan 9
KR - Corea 7
PH - Filippine 7
CO - Colombia 6
GR - Grecia 6
IQ - Iraq 6
SA - Arabia Saudita 6
EC - Ecuador 5
ES - Italia 5
IR - Iran 5
LB - Libano 5
TW - Taiwan 5
CR - Costa Rica 4
IL - Israele 4
KE - Kenya 4
PY - Paraguay 4
RO - Romania 4
VE - Venezuela 4
AU - Australia 3
CZ - Repubblica Ceca 3
JM - Giamaica 3
LT - Lituania 3
MY - Malesia 3
AL - Albania 2
EG - Egitto 2
LV - Lettonia 2
MA - Marocco 2
OM - Oman 2
PT - Portogallo 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BZ - Belize 1
CL - Cile 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GI - Gibilterra 1
GP - Guadalupe 1
GT - Guatemala 1
HT - Haiti 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
QA - Qatar 1
RS - Serbia 1
RW - Ruanda 1
UY - Uruguay 1
Totale 9.343
Salva come PNG Salva come JPEG
Città #
Singapore 604
Southend 590
Ashburn 396
Fairfield 306
Chandler 301
Santa Clara 227
Houston 193
Hong Kong 169
San Jose 163
Ann Arbor 156
Bologna 149
Wilmington 143
Seattle 139
Woodbridge 130
Ho Chi Minh City 118
Princeton 115
Beijing 106
Cambridge 101
Hanoi 100
Lomé 92
Dong Ket 82
Dublin 81
Boardman 80
Padova 59
Tokyo 56
Westminster 55
Nanjing 54
Council Bluffs 51
Lauterbourg 48
Milan 42
Abeokuta 41
New York 37
Abidjan 36
Helsinki 36
Shenyang 36
Jinan 35
Redwood City 34
Saint Petersburg 34
Changsha 32
Medford 32
Los Angeles 29
Berlin 27
Sofia 27
Brussels 25
Buffalo 24
Nanchang 24
Amman 23
Hebei 23
Turin 23
Frankfurt am Main 22
Redondo Beach 22
Shanghai 20
Guangzhou 19
Dallas 18
Rome 16
Vienna 16
Bern 15
San Diego 15
Da Nang 14
Jiaxing 14
Munich 14
Falls Church 13
Haiphong 13
Hangzhou 12
Jacksonville 12
Menlo Park 12
Montreal 12
Amsterdam 11
Norwalk 11
Phoenix 11
The Dalles 11
Tianjin 11
Toronto 11
Warsaw 11
Bremen 10
Orem 10
São Paulo 10
Tappahannock 10
Yubileyny 10
Dearborn 9
San Francisco 9
Zhengzhou 9
Florence 8
Haikou 8
Hải Dương 8
London 8
Turku 8
Valsamoggia 8
Biên Hòa 7
Brooklyn 6
Bühl 6
Istanbul 6
Lanzhou 6
Mountain View 6
Taizhou 6
Andover 5
Baghdad 5
Boston 5
Can Tho 5
Chennai 5
Totale 6.033
Salva come PNG Salva come JPEG
Nome #
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 287
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 275
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 259
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 238
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 234
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 231
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 229
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 229
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 223
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 221
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 218
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 212
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 210
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 206
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 204
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS 203
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 187
Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. 186
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 178
Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. 178
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 177
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 176
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 174
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 170
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 165
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 164
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 162
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 161
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 161
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 156
Nuclear inositide signaling in myelodysplastic syndromes. 153
Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study 153
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 150
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 148
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 144
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 144
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 141
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 140
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 140
GENE EXPRESSION OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS IN MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 131
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 130
Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. 130
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 127
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 127
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 127
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 126
Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera. 125
Long-lasting hematologic response to azacitidine in myelodysplastic syndromes: Multicenter retrospective study of 36 patients 118
ROLE OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS ON EPO-INDUCED EYTHROID DIFFERENTIATION IN LOW-RISK MDS PATIENTS 116
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. 116
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 107
null 103
PROSPECTIVE PHASE II STUDY ON LOW-DOSE 5-AZACYTIDINE FOR TREATMENT OF SYMPTOMATIC PATIENTS WITH LOW/INT-1 RISK MYELODISPLASIA 102
PI-PLCBETA1 GENE METHYLATION AND EXPRESSION AS A RELIABLE AND DYNAMIC MARKER OF CLINICAL RESPONSE TO 5-AZACYTIDINE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES 88
null 72
IS PI-PLC 1 EXPRESSION A RELIABLE PREDICTOR OF RESPONSE IN LOW RISK MDS PATIENTS TREATED WITH LOW-DOSE AZACITIDINE? RESULTS OF A PROSPECTIVE MULTICENTRIC STUDY 72
null 71
PKR is activated in MDS patients and its subcellular localization depends on disease severity. 56
null 43
null 41
Totale 9.515
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.790
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.790
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.007 0 16 57 97 98 72 36 49 39 150 177 216
2022/20231.301 100 176 77 181 116 96 59 118 206 13 100 59
2023/2024411 21 58 33 36 51 71 14 15 26 55 13 18
2024/20251.120 47 145 86 76 283 77 78 38 11 56 23 200
2025/20262.502 182 218 194 120 338 171 327 86 465 196 103 102
2026/2027119 42 77 0 0 0 0 0 0 0 0 0 0
Totale 9.515